During the past decade, Centro Cuore Morgagni conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Cuore Morgagni" #1 collaborator was "Chiltern International Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Centro Cuore Morgagni" are "Atrial Fibrillation" (2 trials). Many other conditions were trialed in "Centro Cuore Morgagni" in a lesser frequency.

Most popular intervention types in "Centro Cuore Morgagni" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Edoxaban" (1 trials), "Edoxaban-based Regimen" (1 trials) and "VKA-based Regimen" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centro Cuore Morgagni" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Centro Cuore Morgagni". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Centro Cuore Morgagni, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centro Cuore Morgagni, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".